1. Home
  2. FNLC vs DMAC Comparison

FNLC vs DMAC Comparison

Compare FNLC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

HOLD

Current Price

$27.84

Market Cap

288.7M

Sector

Finance

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$9.40

Market Cap

457.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNLC
DMAC
Founded
1864
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.7M
457.2M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
FNLC
DMAC
Price
$27.84
$9.40
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
17.1K
581.8K
Earning Date
01-21-2026
11-12-2025
Dividend Yield
5.32%
N/A
EPS Growth
18.07
N/A
EPS
2.81
N/A
Revenue
$88,119,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.90
N/A
Revenue Growth
12.70
N/A
52 Week Low
$22.11
$3.19
52 Week High
$28.71
$10.42

Technical Indicators

Market Signals
Indicator
FNLC
DMAC
Relative Strength Index (RSI) 71.52 69.32
Support Level $25.94 $7.76
Resistance Level $26.42 $10.42
Average True Range (ATR) 0.51 0.71
MACD 0.22 0.09
Stochastic Oscillator 97.19 64.37

Price Performance

Historical Comparison
FNLC
DMAC

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: